Does Rallies show Form 4 insider transactions for ABUS?

Yes. Rallies tracks ABUS insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is ABUS research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ABUS. It does not provide personalized investment advice.

ABUS (Arbutus Biopharma Corporation Common Stock) Stock Analysis - Insider Trades

Arbutus Biopharma Corporation Common Stock (ABUS) is a publicly traded Healthcare sector company. As of May 20, 2026, ABUS trades at $4.36 with a market cap of $823.73M and a P/E ratio of 5.20. ABUS moved +3.81% today. Year to date, ABUS is -7.22%; over the trailing twelve months it is +36.14%. Its 52-week range spans $2.71 to $5.10. Rallies surfaces ABUS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading ABUS stock inside the company?

Recent ABUS insider activity includes HASTINGS DAVID C sold 22.18K, Sims Karen sold 19.35K, McElhaugh Michael J. sold 23.79K, Naftzger J. Christopher sold 11.33K, and MANCHESTER KEITH S sold 8.85K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

ABUS Key Metrics

Key financial metrics for ABUS
Metric	Value
Price	$4.36
Market Cap	$823.73M
P/E Ratio	5.20
EPS	$0.84
Dividend Yield	0.00%
52-Week High	$5.10
52-Week Low	$2.71
Volume	2.19M
Avg Volume	0
Revenue (TTM)	$191.44M
Net Income	$160.72M
Gross Margin	0.00%

Recent ABUS Insider Trades

HASTINGS DAVID C sold 22.18K (~$72.83K) on Feb 4, 2025.
Sims Karen sold 19.35K (~$63.52K) on Feb 4, 2025.
McElhaugh Michael J. sold 23.79K (~$78.10K) on Feb 4, 2025.
Naftzger J. Christopher sold 11.33K (~$37.21K) on Feb 4, 2025.
MANCHESTER KEITH S sold 8.85K (~$32.64K) on Aug 14, 2024.

Latest ABUS News

Moderna Q1 Revenue Triples to $389M with $311M International COVID Sales — May 1, 2026
Arbutus Biopharma Secures FDA Fast Track for Imdusiran After 10 HBV Functional Cures — Apr 15, 2026
Arbutus Secures $2.25B Moderna Settlement and Reports $91.5M Cash Position — Mar 23, 2026
Arbutus to Receive $950M Upfront, Up to $2.25B From Moderna Settlement — Mar 4, 2026
Arbutus Biopharma to Receive Share of $950M Moderna Settlement, Eyeing $1.3B Appeal Upside — Mar 4, 2026

ABUS Analyst Consensus

ABUS analyst coverage data. Average price target: $0.00.

Common questions about ABUS

Who is trading ABUS stock inside the company?: Recent ABUS insider activity includes HASTINGS DAVID C sold 22.18K, Sims Karen sold 19.35K, McElhaugh Michael J. sold 23.79K, Naftzger J. Christopher sold 11.33K, and MANCHESTER KEITH S sold 8.85K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for ABUS?: Yes. Rallies tracks ABUS insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is ABUS research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ABUS. It does not provide personalized investment advice.